Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Anude, Chuka J ^a,b   Eze, Emeka ^c   Onyegbutulem, Henry C ^d   Charurat, Man ^a   Etiebet, Mary Ann ^a   Ajayi, Samuel ^e   Dakum, Patrick ^a,f   Akinwande, Oluyemisi ^f   Beyrer, Chris ^b   Abimiku, Alash'le ^a   Blattner, William ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF BENIN   (Nigeria)

^d Asokoro Hospital   (Nigeria)

^e UNIVERSITY OF ABUJA   (Nigeria)

^f INSTITUTE OF HUMAN VIROLOGY NIGERIA   (Nigeria)

Author keywords

Anemia; Anti retroviral therapy; Immuno virologic discordance; Immuno virologic outcomes; Nigeria; PEPFAR; Sub Saharan Africa; Treatment failure; Viral load testing

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; HEMOGLOBIN; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AGE; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG TREATMENT FAILURE; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NIGERIA; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; RANDOM SAMPLE; SEX DIFFERENCE; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANEMIA; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; NIGERIA; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84874397717     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-113     Document Type: Article

References (57)

1. Apisarnthanarak A. Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med 2008, 9(5):322-325. 10.1111/j.1468-1293.2008.00562.x, 18400079.
2. Kitkungvan D. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense. HIV Med 2008,
3. Kamoto K, Aberle-Grasse J. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008, 13(Suppl 2):83-7.
4. Wainberg MA. Two standards of care for HIV: why are Africans being short-changed?. Retrovirology 2009, 6:109. 10.1186/1742-4690-6-109, 2789723, 19951412.
5. Gilks CF. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006, 368(9534):505-10. 10.1016/S0140-6736(06)69158-7, 16890837.
6. Steele KT. Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in botswana. PLoS One 6(6):20010.
7. Keiser O. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. Aids 2011, 25(14):1761-9. 10.1097/QAD.0b013e328349822f, 21681057.
8. Sungkanuparph S. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol 2008, 41(4):310-3. 10.1016/j.jcv.2007.12.015, 18316243.
9. Sungkanuparph S. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007, 44(3):447-52. 10.1086/510745, 17205457.
10. Ferradini L. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367(9519):1335-42. 10.1016/S0140-6736(06)68580-2, 16631912.
11. Calmy A. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006, 20(8):1163-9. 10.1097/01.aids.0000226957.79847.d6, 16691068.
12. Laurent C. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002, 16(10):1363-70. 10.1097/00002030-200207050-00008, 12131213.
13. WHO Anti-retroviral therapy for HIV infection in adults and adolescents 2010, revision: recommendations for a public health approach, WHO.
14. Loutfy MR. CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. J Infect Dis 2005, 192(8):1407-11. 10.1086/466537, 16170758.
15. Tan R. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47(5):553-8. 10.1097/QAI.0b013e31816856c5, 18285713.
16. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993, 138(11):923-36.
17. Maldonado G, Greenland S. Interpreting model coefficients when the true model form is unknown. Epidemiology 1993, 4(4):310-8. 10.1097/00001648-199307000-00006, 8347741.
18. Smith DJ. Premarital sex, procreation, and HIV risk in Nigeria. Stud Fam Plann 2004, 35(4):223-35. 10.1111/j.0039-3665.2004.00027.x, 15628781.
19. Djomand G. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003, 17(Suppl 3):S5-15.
20. Ramadhani HO. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007, 45(11):8-1492.
21. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs 2005, 49(6):23-616.
22. Taiwo BO. Assessing the Viorologic and Adherence Benefits of Patient-Selected HIV Treatment Partners in a Resource-limited 2009, J Acquir Immune Defic Syndr: Setting.
23. Taiwo BO. Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial. J Acquir Immune Defic Syndr. 54(5):5-563.
24. Isa SE. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria. Niger J Med 19(3):85-279.
25. Barth RE. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10(3):66-155.
26. Coetzee D. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004, 18(6):887-95. 10.1097/00002030-200404090-00006, 15060436.
27. Wester CW. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005, 40(3):336-43. 10.1097/01.qai.0000159668.80207.5b, 16249709.
28. Gallant JE. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354(3):251-60. 10.1056/NEJMoa051871, 16421366.
29. Gallant JE. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292(2):191-201. 10.1001/jama.292.2.191, 15249568.
30. Pozniak AL. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006, 43(5):535-40.
31. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19(1):29-33. 10.1097/00042560-199809010-00004, 9732065.
32. Toure S. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 2008, 22(7):873-82. 10.1097/QAD.0b013e3282f768f8, 18427206.
33. Dabis F. Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005, 34(5):979-86.
34. Smith JL, Brooker S. Impact of hookworm infection and deworming on anaemia in non-pregnant populations: a systematic review. Trop Med Int Health 2010, 15(7):776-95. 10.1111/j.1365-3156.2010.02542.x, 2916221,2916221, 20500563.
35. Glass TR. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006, 41(3):385-92. 10.1097/01.qai.0000186371.95301.52, 16540942.
36. Gordillo V. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999, 13(13):1763-9. 10.1097/00002030-199909100-00021, 10509579.
37. Charurat M. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One 5(5):10584.
38. Pettifor A. Early coital debut and associated HIV risk factors among young women and men in South Africa. Int Perspect Sex Reprod Health 2009, 35(2):82-90. 10.1363/3508209, 19620092.
39. Speizer IS. Sexual violence and reproductive health outcomes among South African female youths: a contextual analysis. Am J Public Health 2009, 99(Suppl 2):S425-31. 3515795, 19372525.
40. Kaestle CE. Young age at first sexual intercourse and sexually transmitted infections in adolescents and young adults. Am J Epidemiol 2005, 161(8):774-80. 10.1093/aje/kwi095, 15800270.
41. Posse M. Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health 2008, 13(7):904-13. 10.1111/j.1365-3156.2008.02091.x, 18466183.
42. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004, 18(Suppl 3):S21-5.
43. van Oosterhout JJ. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health 2005, 10(5):464-70. 10.1111/j.1365-3156.2005.01409.x, 15860093.
44. Bhat VG. Factors associated with poor adherence to anti-retroviral therapy in patients attending a rural health centre in South Africa. Eur J Clin Microbiol Infect Dis 29(8):-53-947.
45. Marc LG. Educational attainment and response to HAART during initial therapy for HIV-1 infection. J Psychosom Res 2007, 63(2):207-16. 10.1016/j.jpsychores.2007.04.009, 17662759.
46. Grabar S. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133(6):401-10.
47. Keiser O. Antiretroviral therapy in resource-limited settings. to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health, 2008 1996, 13(7):9-870.
48. Braitstein P. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008, 17(1):47-55.
49. Nash D. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008, 22(17):2291-302. 10.1097/QAD.0b013e3283121ca9, 2794130, 18981768.
50. Moore DM. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005, 40(3):288-93. 10.1097/01.qai.0000182847.38098.d1, 16249702.
51. Goossens VJ. A delay in CD4 cell response after initiation of highly active antiretroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodies. Aids 2002, 16(12):1682-4. 10.1097/00002030-200208160-00015, 12172091.
52. Gilson RJ. Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 11(2):60-152.
53. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008, 8:89. 10.1186/1471-2334-8-89, 2459184, 18601727.
54. Lundgren JD. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008, 197(8):1145-55.
55. Kantor R. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009, 49(3):454-62. 10.1086/600396, 19569972.
56. Zoufaly A. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis 2011, 203(3):364-71. 10.1093/jinfdis/jiq055, 3130441, 21208929.
57. Mugyenyi P. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375(9709):31-123.